Akero Therapeutics Dirección

Dirección controles de criterios 3/4

Akero Therapeutics' CEO is Andrew Cheng, appointed in Sep 2018, has a tenure of 5.67 years. total yearly compensation is $8.83M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $9.52M. The average tenure of the management team and the board of directors is 5.6 years and 5.1 years respectively.

Información clave

Andrew Cheng

Chief Executive Officer (CEO)

US$8.8m

Compensación total

Porcentaje del salario del CEO	7.5%
Permanencia del CEO	5.7yrs
Participación del CEO	0.7%
Permanencia media de la dirección	5.6yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Oct 01

Akero: Ticking All The Right Boxes In NASH

Sep 23

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Jun 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrew Cheng en comparación con los beneficios de Akero Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$179m
Dec 31 2023	US$9m	US$660k	-US$152m
Sep 30 2023	n/a	n/a	-US$120m
Jun 30 2023	n/a	n/a	-US$116m
Mar 31 2023	n/a	n/a	-US$112m
Dec 31 2022	US$10m	US$624k	-US$112m
Sep 30 2022	n/a	n/a	-US$121m
Jun 30 2022	n/a	n/a	-US$110m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$570k	-US$101m
Sep 30 2021	n/a	n/a	-US$98m
Jun 30 2021	n/a	n/a	-US$95m
Mar 31 2021	n/a	n/a	-US$82m
Dec 31 2020	US$5m	US$523k	-US$79m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$59m
Mar 31 2020	n/a	n/a	-US$50m
Dec 31 2019	US$5m	US$450k	-US$44m
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$86m
Mar 31 2019	n/a	n/a	-US$87m
Dec 31 2018	US$1m	US$133k	-US$82m

Compensación vs. Mercado: La compensación total de Andrew($USD10.45M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.61M).

Compensación vs. Ingresos: La compensación de Andrew ha sido consistente con los resultados de la empresa en el último año.

CEO

Andrew Cheng (56 yo)

5.7yrs

Permanencia

US$8,834,907

Compensación

Dr. Andrew Cheng, MD, PhD, serves as Director of Vera Therapeutics, Inc. since May 2017. He served as Director of Arbutus Biopharma Corporation since August 17, 2019 until May 25, 2022. He served as Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Cheng	President	5.7yrs	US$8.83m	0.67% $ 9.5m
Jonathan Young	Co-Founder	5.7yrs	US$3.44m	0.39% $ 5.6m
Timothy Rolph	Co-Founder & Chief Scientific Officer	7.1yrs	US$3.49m	0.20% $ 2.8m
William White	Executive VP	5.1yrs	US$4.29m	0.0057% $ 81.1k
Catriona Yale	Executive VP & Chief Development Officer	5.6yrs	US$3.45m	0.046% $ 659.8k
Scott Gangloff	Chief Technology Officer	less than a year	sin datos	sin datos
Patrick Lamy	Senior Vice President of Commercial Strategy	1.3yrs	sin datos	sin datos
John Schembri	VP of Finance & Controller	no data	sin datos	sin datos

5.6yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AKRO es experimentado (5.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Cheng	President	6.3yrs	US$8.83m	0.67% $ 9.5m
Seth Harrison	Independent Director	5.1yrs	US$568.56k	0.41% $ 5.9m
Jane Pritchett Henderson	Independent Director	5.1yrs	US$586.06k	0% $ 0
Mark Iwicki	Independent Chairman of the Board	5.5yrs	US$606.06k	0% $ 0
Tomas Heyman	Independent Director	3.9yrs	US$581.06k	0% $ 0
Graham L. Walmsley	Independent Director	5.9yrs	US$578.56k	0.0031% $ 44.8k
Yuan Xu	Independent Director	3.1yrs	US$573.56k	0% $ 0
Judy Chou	Independent Director	2.8yrs	US$571.06k	0% $ 0

5.1yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de AKRO se considera experimentada (5 años de antigüedad promedio).

Akero Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Co-Founder notifies of intention to sell stock

President notifies of intention to sell stock

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Recent updates

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

High number of new directors

President exercised options and sold US$170k worth of stock

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

President exercised options and sold US$169k worth of stock

Executive VP exercised options and sold US$146k worth of stock

We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

President exercised options and sold US$189k worth of stock

Executive VP exercised options and sold US$99k worth of stock